Results 181 to 190 of about 19,663 (194)

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Annals of Oncology, 2019
Renaud Sabatier, Alexis B Cortot, V Haddad   +2 more
exaly  

Crizotinib-induced esophageal ulceration: A novel adverse event of crizotinib

Lung Cancer, 2013
Susumu Hijioka, Toyoaki Hida, Chiaki Kondo   +2 more
exaly  

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects

European Journal of Clinical Pharmacology, 2015
Weiwei Tan, Akintunde Bello
exaly  

Heart rate decrease during crizotinib treatment and potential correlation to clinical response

Cancer, 2013
Sai-Hong Ou
exaly  

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Journal of Thoracic Oncology, 2019
Anne-Marie Dingemans, Mariano Provencio, Niki Karachaliou   +2 more
exaly  

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

Journal of Clinical Pharmacology, 2015
Weiwei Tan, Akintunde Bello
exaly  

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Clinical Lung Cancer, 2013
Robert C Doebele, Anna E Baron, Benjamin J Solomon   +2 more
exaly  

Crizotinib

Reactions Weekly, 2020
openaire   +1 more source

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

British Journal of Pharmacology, 2012
Kenneth Kin Wah To, Wang Xiaokun, Wang Zhou   +2 more
exaly  

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Annals of Oncology, 2017
Jean-Yves Blay, Agnieszka Wozniak, Silvia Stacchiotti   +2 more
exaly